Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNA PRIME: RNA-LP Vaccines in Pediatric Recurrent Intracranial Malignancies and Solid Tumors
NCT05660408Phase 2Active, not recruiting
- Sponsor
- University of Florida
- Start
- Mar 2025
- Primary completion
- Oct 2033
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pp65 RNA-LPs, phosphoprotein 65 messenger RNA-lipid particles + tumor messenger RNA-lipid particles in glioma, osteosarcoma (OS), sponsored by University of Florida. Started Mar 2025; status: active, not recruiting.
02
Drugs
pp65 RNA-LPsphosphoprotein 65 messenger RNA-lipid particles + tumor messenger RNA-lipid particles
03
Conditions
gliomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT05660408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660408.